<SEC-DOCUMENT>0000950170-23-026811.txt : 20230607
<SEC-HEADER>0000950170-23-026811.hdr.sgml : 20230607
<ACCEPTANCE-DATETIME>20230607160758
ACCESSION NUMBER:		0000950170-23-026811
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20230606
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230607
DATE AS OF CHANGE:		20230607

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		23999037

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>staa-20230606.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-06-07T16:05:30.9891+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:staa="http://www.staar.com/20230606" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_5f3bf559-4bed-4b48-8435-45a60bcc44e8" name="dei:AmendmentFlag" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric id="F_caad0dfd-bb78-4bfb-8e49-7af52971d461" name="dei:EntityCentralIndexKey" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4">0000718937</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="staa-20230606.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000718937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-06</xbrli:startDate><xbrli:endDate>2023-06-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="margin-left:37.213%;text-indent:0.0%;font-size:10.0pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:34.417%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="margin-left:14.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:11.833%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="margin-left:37.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:34.954%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_99a55c19-ad9a-4ab4-a7e6-6f6941bacbf2" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:32.987%;text-indent:0.036%;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:30.213%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:16.96%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:14.731%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of report (Date of earliest event reported):  </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d008fc76-f60e-4032-bee3-f76319bce8c2" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 6, 2023</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:30.187%;text-indent:0.0%;font-size:10.0pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.019%;text-align:center;"><span style="font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3aaac5cc-4df1-49f3-b105-44b26235661d" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STAAR Surgical Co</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mpany</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:30.133%;text-indent:0.0%;font-size:10.0pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.0%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact Name of Registrant as Specified in Charter)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8dbb2754-f6bf-4157-a7dc-f98575b2f2b1" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78e1dacd-6295-4cf3-8cac-2a764f7c3dc0" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0-11634</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5f7a0911-32a2-46dc-af1f-73974fa54ec9" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95-3797439</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_846a0eb6-9864-4aa2-8178-7c279e9d9af4" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25651 Atlantic Ocean Drive</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf9b9b66-377c-4760-a797-173b4c3dc7e6" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lake Forest</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24757991-b55d-46b5-bf4a-f4c27f0976f5" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f65b7749-9fa3-4358-8ded-330d08cd8f6c" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92630</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe46b221-2ded-4663-a80a-8a8929cb005f" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">626</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_405eee5d-1118-48b7-b458-a9507634320b" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">303-7902</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.926%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Instruction A.2. below):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_23d5baa2-3c00-4da4-b523-17eaa6c35a25" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_4a8584ab-a267-4610-8f31-859570dc8e31" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_f1ba563e-ee46-42aa-b28b-f52bb74cb669" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_ce171fe3-7061-449d-9bf4-41fb5b299412" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c1fcb29a-8ae4-42ce-8483-8b5caf83f702" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_488ef51a-aaf7-4c84-bb42-9d898ec0e8c3" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STAA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_90723512-1eb5-4e80-a0c7-68004bdc5ab3" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NASDAQ</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.593%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_7a11fb32-345c-4e45-ba1b-74c6dad42763" contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.519%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.519%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.519%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 6, 2023, STAAR Surgical Company (the &#34;Company&#34;) participated in the William Blair 43rd Annual Growth Stock Conference (the &#34;Conference&#34;).  The Company's participation in the Conference was webcast and a copy of the transcript is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.896%;"></td>
    <td style="width:1.4%;"></td>
    <td style="width:1.643%;"></td>
    <td style="width:82.061%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="staa-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transcript of the Company's participation in the Conference held on June 6, 2023.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.0%;"></td>
    <td style="width:3.2%;"></td>
    <td style="width:81.8%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STAAR Surgical Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 7, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Tom Frinzi</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thomas G. Frinzi</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>staa-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(24,24,24,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Name: STAAR Surgical Company (STAA)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Event: William Blair 43rd Annual Growth Stock Conference</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: June 06, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;&lt;Margaret Kaczor, Analyst, William Blair&gt;&gt;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Good afternoon everyone. Thanks for coming out to the William Blair Growth Stock Conference. My name is Margaret Kaczor. I am the Research Analyst at William Blair, who covers STAAR Surgical. I am required to inform you that you can obtain a complete list of research disclosures or potential conflicts of interest at williamblair.com.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With that said, I'm pleased to introduce Tom Frinzi, CEO; and Patrick Williams, CFO of STAAR Surgical.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;&lt;Thomas G. Frinzi, President and Chief Executive Officer&gt;&gt;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sure. Thank you, Margaret, and good afternoon everyone again. My name is Tom Frinzi. I'm the CEO and Chair of STAAR Surgical. I'm joined by Patrick Williams, our CFO. And in the back room, Brian Moore, who is our Vice President of Investor Relations. I would direct you to our safe harbor regarding the forward-looking statements. And let me introduce STAAR to all of you by first introducing myself. I became the CEO in January of this year, having been on the board of STAAR since 2020 and having spent nearly 40 years in the field of surgical ophthalmology, so I'm very excited about the opportunity to lead this high growth organization.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Who is STAAR? It's pretty straightforward. We develop, we manufacture and we market a premium implantable contact lens that we refer to as an implantable Collamer Lens, which is our unique material. And our passion, our goal, our strategy for the business is really to become the first choice for doctors and patients seeking visual freedom. Clearly, our reach is global. We're in 75 countries with direct, hybrid and distributor relationships. And over the past five years, we've had a compounded annual growth rate of 32% with our strongest region in the Asia Pacific market.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">What we do? We provide a proprietary lens technology to our customer, the ophthalmologist in terms of treating refractive error, in particular myopia or nearsightedness, through a very simple, straightforward procedure that takes about 20 minutes bilaterally. And as the schematic on the left demonstrates it is not a difficult procedure, but it's a delicate procedure because we place the implant behind the color part of your eye, the iris, and in front of the natural crystalline lens in an anatomical structure referred to as the sulcus. And that lens sits there quietly in terms of our demographic for 30, 40, up to 50 years until such time as the patient forms a cataract and then has to have it removed for ultimately cataract surgery. Our value proposition is pretty impactful, both from a doctor point of view and from a patient point of view. When you think about no capital investment, preserve the integrity and strength of the cornea, the outcomes from a quality of vision and quantity of vision are really best-in-class. The technology is removable if needed by a physician. And last but not least, our material Collamer is very biocompatible and very quiet in the eye.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Throughout my career, I believe two things make a successful company. One, do you have a large market opportunity? And two, does the technology work? And I think over the next several slides, you'll be able to determine that we, STAAR, check both those boxes highly well. We have a large market opportunity in front of us, not only for today, but tomorrow with 2 billion people suffering from myopia or nearsightedness. And market research would suggest that by the year 2050, there is going to be 5 billion people suffering from myopia. A little closer to home, here in the United States, a lot of people don't realize contact lens dropouts in this country every year, are six million patients or 12 million eyes. So, when you think about a relatively large market opportunity, one could suggest that the runway for our technology is very, very attractive. Today's refractive market is about 4.5 million procedures, where EVO controls about 12% of that market, up from about 3% just five years ago.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In terms of does the technology work? I think when you think about two million implants, over 200 clinical papers published, the fact that high patient satisfaction, 99.4% patients postoperatively happy with their procedure, the safety and the efficacy of our technology has been well established.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">So, let me turn my attention to our financial performance. Over the past five years our performance in terms of top line growth speaks for itself and we remain committed and confident in continuing that trend.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to market scope analysis in 2022, when compared to ophthalmic peers, be they big, small, public or private, clearly STAAR is outpacing competition. The gray bars refer to our total sales, the blue bars refer to ICL specific sales. And throughout 2022, per quarter, we continue to outpace the market.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">But it's not just about top line growth. So this slide certainly demonstrates that we have a solid history of being fiscally prudent, and that will certainly continue under my tenure. We will utilize our strong balance sheet to invest wisely and stay focused on driving gross margin expansion above market operating margins, while maintaining top line sales growth.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">So, you may be thinking why invest in STAAR? I think the simple answer is we perform. And when you look at this, it's a great chart to demonstrate that when you consider small to mid-cap public companies in the Med. device sector, there is only two that have driven 20 plus percent top line growth and GAAP earnings per share. And STAAR is one of those.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Another reason to invest with STAAR Surgical is the fact that there is very little meaningful competition. Our 20-year history, our first-mover advantage and our unique column or material has really created a mote around our business. Many have tried as the graphics on the right suggest but very few have succeeded. And STAAR continues to dominate this particular market segment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Another reason is the market opportunity as you move down the diopter curve, is extremely, extremely attractive. STAAR has been very successful by going wide in the marketplace by treating the amount of high myopia that's out there. But as this slide suggests, the opportunity under eight diopters versus above eight diopters grows exponentially. We can increase our market opportunity 4x as we move down that diopter curve, and we're committed to doing that. Another reason to invest is certainly new geographies and products, and the newest geography we've entered into just in the last 12 months is this U.S. market.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">And I know there's been a lot of questions about the U.S. market, and I think I'm here to tell you, where we need to be at this point in time. But the U.S. market is very unique. It's different than every other market we've gone into. And I think it's a question of when we hit that inflection point, not if we hit that inflection point and we're focused on doing the right things, both in terms of an investment point of view and surrounding our customers so we can go deep in customers as opposed to wide. But I think another reason is our product portfolio, and we're going to enter the presbyopic market and we're excited about that with EVO Viva, where we can begin to appeal to early presbyopic patients ages 45 to 55 in particular. That product is CE Mark currently. We've had a very small scale, very focused commercial effort in Europe as we've learned how to position the product appropriately.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">And I think by the end of this year and going into 2024, you'll hear more about the excitement we feel about this product and entering the presbyopic market. We've also tried to be very smart about where we've made investments and we've been disciplined about where we're investing product and our money in our product. And I think there's three that make sense for us. One was creating patient awareness through the celebrity and influencers and the graphics on the right look to the Jonas Brothers relationship. Max Strus, who's a member of the Miami Heat that's in the NBA finals right now, I've told people earlier today that I think the reason why The Heat are in the finals is because of EVO.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Now, we can't claim that, but I'm convinced that that had something to do with it, because Max Strus is having the best year he is ever had and his three point average has certainly gone up. But Peyton List, another influencer and actress have all really helped in the United States build brand awareness, Seung Jeong in South Korea a very recognizable name in that marketplace. And our unaided awareness as we've made these kinds of investments and that market is up over 90%. In the U.S., through the use of the individuals that are U.S. focused. Our aided awareness is up to 34% from the mid to high-teens. So clearly the investment in patient awareness is working.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Secondly, we&#x2019;ve increased our customer facing organization. We&#x2019;ve invested in account executives, clinical application specialists, practice development, managers to really surround the customers, so we can go deeper in those accounts.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">And last but not least, we&#x2019;re measuring the return on those investments to ensure through Patrick and his organization that where we are spending money that investment is being rewarded. I think we&#x2019;re developing a culture of high performance at STAAR Surgical, where we are getting all of our functions, be they commercial, be they operational, be they clinical, be they regulatory, or be they finance to really work together and focus on how do we continue to increase surge in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">confidence? How do we continue to increase our manufacturing capability and efficiency and create a company that&#x2019;s easy to do business with.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Q1 results, again speak for themselves. Q1 results with 20%-plus growth and the outlook we issued on May 3 showing continued strong performance with ICL growth at 28%. So in summary, I would say there&#x2019;s a myriad of reasons why you want to invest with STAAR. So I thank you for your time and attention. I know it&#x2019;s late in the day, it&#x2019;s been a long day for us, but we believe it&#x2019;s our time. We believe it&#x2019;s lens-based refractive surgeries time. And I hope for you &#x2013; those of you that have not invested with us, we&#x2019;ve piqued your interest such that it&#x2019;s really maybe your time to consider STAAR.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">So with that, thank you, and happy to take any questions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Q&amp;A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: Perfect. So obviously in the crowd, feel free to ask questions. We&#x2019;ll repeat them on our end. So folks on the webcast will be able to hear them. But maybe just to start, Tom, I think one of the slides specifically talked about that it&#x2019;s a matter of when not if that EVO becomes frankly bigger than it is in China, which I think is 25%.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah, it&#x2019;s approach, it&#x2019;s really closer. The thing about China is that market continues to grow. So the 25% was based upon a market that was maybe about 1.1 million, 1,2 million. That market&#x2019;s now up to 1.5 million procedures. So I think our share is probably right around 20% to 21%. But your point&#x2019;s well taken. How long is it going to take us to get there in the U.S.?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: Yeah, bridge me from here to that.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Listen, I think it&#x2019;s probably, when you think about China put it in context, when we first got into that market and started to see an inflection was 2016. So about late 2018, early 2019, roughly a 24-month period of time for us to really see the kind of adoption we see now in China. When you think about where we are in the U.S., we&#x2019;re a little over one year post-approval, but I would submit to you that we really haven&#x2019;t been in a launch mode until probably late fourth quarter of 2022. So maybe we&#x2019;re six, seven, eight months into a launch mode. And I think another 18 to 24 months on top of that, end of 2024 into 2025.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I think we&#x2019;ll be in a position where we start to see the kind of adoption rate in this market that we have around the world.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: Okay. And then there was one slide that I think had the guidance rate range. So maybe Patrick for you, how do you think about the U.S. within that guidance range on a total company basis?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Patrick F. Williams&gt;: Sure. So we got the question, I think it was Slide 13 or 14, where &#x2013; number one, we think of our overall company, right, global revenue for us. And so when &#x2013; in the context of the slides we were showing from 2017 to 2023 and it&#x2019;s our policy that we&#x2019;re not going to update guidance centric quarter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and is why we put up there as of May 3. And so the question I think we got that wasn&#x2019;t necessarily in the slide deck is, well, what about the $30 million or</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approximately $30 million for the U.S. that you just asked? The response is the same as of May 3. It was approximately $30 million for the U.S., which adds up to the $348 million in totality. The company will of course adjust guidance up, down, keep it even as we deem appropriate. And normally that&#x2019;s around our next earnings call.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: All right. Apparently people like hearing my questions, so we&#x2019;ll keep going on this one.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: They&#x2019;re all tired, Marty. They&#x2019;re all tired.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: We do have coffee outside. Okay. So maybe let&#x2019;s talk a little bit on China, we&#x2019;ll get back to the U.S. But what are you guys seeing on China, especially with some of the COVID cases and the rise that we&#x2019;re seeing there?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah. It&#x2019;s interesting. Several weeks ago, as many of you know, some articles came out about a spike in COVID, obviously, because we have a high percentage of our revenue coming out of China. We certainly saw the impact in a negative way on our stock price. But we talked to China almost on a daily basis and quite frankly, we were surprised in our contacts and our leadership in China was equally surprised.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This was news two months ago. There was beginning to see spikes in COVID, but quite frankly, as I&#x2019;ve told many of you that I met with during today, China has really embraced natural immunity. People got sick, people got better. And we don&#x2019;t believe there&#x2019;s really any material impact to what that new story suggested. We continue to see good in market sales, good activity from our leadership there. So I don&#x2019;t want to say, it was much to do about nothing, but it certainly didn&#x2019;t warrant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the kind of reaction it received in this country.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: So as we think about China and COVID cases and the fact that you guys maybe had a little bit of a slowdown towards the end of last year to shut down in the country. Is there a bolus of cases that at some point we&#x2019;ll come back? Or are you seeing kind of the same demand we had here post-COVID with vacations and travel and spending and so on?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah. As I said, we&#x2019;ve been very pleased with what we&#x2019;re seeing in terms of in-market sales. China is probably averaging about 1,000 procedures a day, and that&#x2019;s very similar to what they were pre-COVID. So, we feel good about China where it is. We said Q1 would be restorative. It was restorative. And we think as we lead into the high season in that particular market, our distributor partner &#x2013; we have a hybrid setup in China where we have 70 people direct employees, and then we work with a distributor that&#x2019;s more like a fulfillment house. So as we sell into the distributor and then they sell through to the marketplace Q2 should be strong, Q3 a lot of that inventory will be carried through. So that&#x2019;s really the high season, and I think we&#x2019;re very well prepared and excited about that.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: And then as it relates to competition, I think you also had a slide on that, which is great. Are you worried at all about the recent competitive entrance in the region? Are you hearing anything?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah. Obviously you always want to be cognizant of competition coming or going. And I think, as I indicated, I think we have such a first mover advantage. Our Collamer material is so unique the way it works in the eye. We do see competition coming, so imitation a good form of flattery. But the early indications are those technologies are competing mainly on price. And clearly, the quality of the outcomes and the quantity of vision that they&#x2019;re driving is not up to speed with EVO. So a physician may go away for a month and evaluate that, but ends up coming back to EVO. So right now, not of heavy concern, but we certainly monitor it.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Patrick F. Williams&gt;: Yeah. And I just wanted to go back to the question about the bolus and all that. And the comment that Tom made. I just want to make sure people understand when we say approximately 1,000 units a day, that number is higher than what it was a year ago, two years ago, and it&#x2019;ll probably be higher next year. And so I know people are starting to do math in their heads and we just want to make sure that that&#x2019;s an approximation. We expect that number to increase in the high season as we work through late June, July and August, which is really their busy season. So that would exceed 1,000 units a day. But I just want to make sure I clarify that for everyone.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: See, you always need finance guys and investor relations guys to keep you honest.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Patrick F. Williams&gt;: Well, I just know that there&#x2019;s some people out there that are listening to every single word.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: That&#x2019;s great job security for everyone involved.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: That&#x2019;s right.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: Okay.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Any questions from the audience? Don&#x2019;t let Margaret do all the work here. I know we&#x2019;ve met with many of you. Good to see you.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah. Well, first and foremost, we invested in our people. We added, as I&#x2019;ve said, more account executives, more practice development people, and more clinical applications people. So, we probably close to double the size of our customer facing organization in the U.S. And that&#x2019;s happening, continues to happen up through this period of time. In terms of programs we&#x2019;re certainly looking at a lot of different areas. We&#x2019;re doing direct-to-consumer advertising that&#x2019;s broadly based. But we&#x2019;re looking at helping physicians consider office-based surgical build out suites. We&#x2019;re certainly considering putting consignments in place to facilitate being more LASIK like in practices that commit the volume. And they all come at a cost. But we continue to look at, and one of the beauties of STAAR being so nimble.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We can react to the uniqueness of every customer, right? And every customer is different, whether it&#x2019;s a setting of care question, whether it&#x2019;s a pricing question, whether it&#x2019;s a training question. And</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we have the resources to be able to react broadly as those come up. Because each individual practice is, is different. And that&#x2019;s one of the uniqueness about this market compared to say, what we experienced in China. China, you have large eye hospitals that move a block of business. You don&#x2019;t have that here in the United States. It&#x2019;s a combination of high volume or high profile practices, low volume, low profile practices, and a lot of blocking and tackling. And that&#x2019;s what we&#x2019;re in the midst of doing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: You also had a slide kind of on the diopter curve and going down that diopter curve. Is that something that&#x2019;s new? Have you been able to see that in the field? What&#x2019;s driving that addition?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah, no, I think look at, when you look at the prevalence, doesn&#x2019;t take a rocket scientist to say, God, if we can come down, particularly in this country. In Asia-Pacific, China in particular, there&#x2019;s a, just given the demographics, there&#x2019;s a disproportionate amount of high myopes. And we have been very successful in China, in a sense staying wide, right? Because there are many high myopes there. In the U.S. that prevalence isn&#x2019;t quite as high. And as that data suggests, there&#x2019;s a 4x opportunity when you go below eight or above eight. And again, slowly but surely, we come in, as I explain to many of you throughout the day, the gateway entry that most people think about EVO ICL and phakic lenses in general is thin corneas and high myopes, right? That&#x2019;s how it&#x2019;s been positioned in the marketplace.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In a sense, if you weren&#x2019;t a good candidate for laser vision correction, then ICL was a very good alternative. It was safe, it was effective. But it was for those that I don&#x2019;t feel comfortable doing laser vision correction on. And that certainly has been our gateway into a lot of practices. And as they do those eyes, they see those outcomes, staff gets excited. We&#x2019;re beginning to see people start coming down from minus 10 to minus nine or minus nine to minus eight. And if it works on eight, why not try it on seven, et cetera, et cetera. Now, we do have some practices, some of the celebrities we&#x2019;ve done were all relatively low myopes, minus three, minus fours, minus fives. That have done very well. In our pivotal trial in the U.S., 32% of the eyes we treated were between minus three and minus six.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">So we know we have the clinical outcomes, the support that it&#x2019;s getting customers comfortable moving that into the fabric of their practice because they&#x2019;re so used to just the minus four walks in the door and they&#x2019;re LVC candidate. What we&#x2019;d like to see is that EVO goes into that conversation, and it&#x2019;s not either or it&#x2019;s an &#x2013; and conversation. And we think as patients, perspective patients hear more and more about the benefits of EVO, maintain the integrity of the cornea, it can be removed, no dry eye, great quality and quantity of vision outcomes. They&#x2019;re going to want to opt for a lens-based solution versus a corneal based solution.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q &#x2013; Margaret Kaczor&gt;: And maybe Tom, this is kind of a generalist audience, so maybe you can walk through why as a patient you would want to have a corneal solution versus a lens-based solution just&#133;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah. Again, I mean, laser vision correction has been around 20 plus years. It&#x2019;s a great procedure throughout my career, and I&#x2019;ve been in it a long time. As I mentioned, I&#x2019;ve benefited personally, I&#x2019;ve had LASIK 25 years ago. Professionally, I&#x2019;ve run businesses where LASIK was a big part of our revenue generation. So I know it&#x2019;s a good procedure. But certainly</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">modifying the cornea versus going in the eye in a very controlled way and putting an implant in. You just don&#x2019;t run the risk of dry eye. You don&#x2019;t weaken the integrity of the cornea by removing tissue. And we are in an additive procedure as opposed to a subtraction procedure. And once you remove that tissue, you can never put it back. But we&#x2019;re preserving the cornea for future innovation. And when you think about ophthalmology, it lives on innovation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">And every two to three years, there&#x2019;s new technology coming out. So by maintaining the integrity of the cornea, we&#x2019;ve made IOL power calculation that much easier when people are ready for cataract surgery. Once you&#x2019;ve modified the cornea, most cataract surgeons will tell you getting the right IOL power then for power calculations for cataract surgery. It&#x2019;s not impossible, but it becomes much more of a challenge. We eliminate all of that by using EVO ICL. So it's just at the end of the day, it's worthy of being in the conversation and just that LASIK has first mover advantage, it's been there for 20, 25 years, people have made a big investment in capital. So I think one of the other things that we see as low hanging fruit for us is the young ophthalmologist coming out of fellowship and train in residency that doesn't have the wherewithal to make the capital investment. They can become a refractive surgeon overnight by moving into a product and technology like EVO ICL, so.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: The least, I'm sorry.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: From my perspective, the least understood about our journey, I think is that the difference between treating a minus 10 and a minus three is no different from a safety point of view, right? Whereas if you treat a minus 10 and a minus three with lasers, there's a big difference in terms of the safety profile. Is that misunderstood or maybe underappreciated might be the better way to look at that. Again I think we anticipated that the U.S. market would take more time. Certainly I did as a board member and as I moved into the operating role recognized that it wasn't going to happen overnight. And maybe that was a little bit different than, than what my predecessor felt. But she also did a wonderful job putting the company in the position that it's in, and I have the advantage of certainly carrying on that legacy, but also being in this industry for 40 years and understanding how to launch products.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: It's a pure cash play &#x2013; pay, so there is no reimbursement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: From a patient point of view, I'd say on the low end bilaterally, both eyes is probably $6,000 on the lowest end, the average is probably $8,000, $4,000 per eye, and the highest I've seen is in the $10,000 to $12,000 range, $5,000 to $6,000 per eye.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Average age is probably 30 to 32. Our approval is I think 20 to 45 minus three up to minus 20.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A&gt;: Yeah. Now, most ophthalmic practices offer patient financing, but yeah, when you&#x2019;re talking about spending that kind of money, but when you put it in context, you&#x2019;re providing just about a lifetime of vision. And certainly vision is such a precious sense, right? And to me you&#x2019;re not going to go and look for the least expensive cardiovascular surgeon if you have a heart condition, right? I would argue vision, people fear losing vision more than just about anything. And to spend $5000 to $10,000 to have really good vision in our case for maybe 40 to 50 years of that young person&#x2019;s life until they develop a cataract, seems to be a reasonable amount of money to spend. Sure.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;Q&gt;: [Question Inaudible]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;A &#x2013; Thomas G. Frinzi&gt;: Yeah, we&#x2019;ve done some analysis in that area, and certainly on a per patient profitability we are actually, depending on setting of care, it can vary a little bit. And what I mean by that is there&#x2019;s probably three different versions. An ambulatory surgery center that&#x2019;s open access that a surgeon goes to and is charged a facility fee, a surgeon owned ambulatory surgery center where he and she can dictate how much the facility fee they want to charge themselves or if they&#x2019;re in an office based surgical suite. Office based surgical suite, probably the profitability is very high in the physician-owned ASC. It&#x2019;s not quite as high, it&#x2019;s just below. And in a open access fee is probably comparable to what laser vision correction is, right?</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">So the surgeon economics are reasonably favorable. And again, I&#x2019;ve often thought that&#x2019;s the third component. If a doc can make money, if it&#x2019;s a big opportunity and the technology works, then it&#x2019;s just about execution. And I think that&#x2019;s what we&#x2019;re about. We have to go out and execute in markets around the world. And we certainly have a history of doing that and I think we&#x2019;ll continue to do that in the U.S. as well. It just is going to take us a little bit more time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;&lt;Margaret Kaczor, Analyst, William Blair&gt;&gt;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">So, I have to apologize, we are out of time, but we will take this to the breakout. That is Jenny A. Thank you guys both.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&lt;&lt;Thomas G. Frinzi, President and Chief Executive Officer&gt;&gt;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yeah. Thank you all. I appreciate it.</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>3
<FILENAME>staa-20230606_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-07T16:05:30.6362+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="staa-20230606.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>staa-20230606_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-07T16:05:30.7648+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>staa-20230606.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-06-07T16:05:30.6411+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.staar.com/20230606" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:staa="http://www.staar.com/20230606" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230606_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230606_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140538381926928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 06, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  06,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STAAR Surgical Co<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000718937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-11634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3797439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25651 Atlantic Ocean Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">303-7902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">STAA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>staa-20230606_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="staa-20230606.xsd" xlink:type="simple"/>
    <context id="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000718937</identifier>
        </entity>
        <period>
            <startDate>2023-06-06</startDate>
            <endDate>2023-06-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_5f3bf559-4bed-4b48-8435-45a60bcc44e8">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_caad0dfd-bb78-4bfb-8e49-7af52971d461">0000718937</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_99a55c19-ad9a-4ab4-a7e6-6f6941bacbf2">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_d008fc76-f60e-4032-bee3-f76319bce8c2">2023-06-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_3aaac5cc-4df1-49f3-b105-44b26235661d">STAAR Surgical Co</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_8dbb2754-f6bf-4157-a7dc-f98575b2f2b1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_78e1dacd-6295-4cf3-8cac-2a764f7c3dc0">0-11634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_5f7a0911-32a2-46dc-af1f-73974fa54ec9">95-3797439</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_846a0eb6-9864-4aa2-8178-7c279e9d9af4">25651 Atlantic Ocean Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_cf9b9b66-377c-4760-a797-173b4c3dc7e6">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_24757991-b55d-46b5-bf4a-f4c27f0976f5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_f65b7749-9fa3-4358-8ded-330d08cd8f6c">92630</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_fe46b221-2ded-4663-a80a-8a8929cb005f">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_405eee5d-1118-48b7-b458-a9507634320b">303-7902</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_23d5baa2-3c00-4da4-b523-17eaa6c35a25">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_4a8584ab-a267-4610-8f31-859570dc8e31">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_f1ba563e-ee46-42aa-b28b-f52bb74cb669">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_ce171fe3-7061-449d-9bf4-41fb5b299412">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_c1fcb29a-8ae4-42ce-8483-8b5caf83f702">Common</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_488ef51a-aaf7-4c84-bb42-9d898ec0e8c3">STAA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_90723512-1eb5-4e80-a0c7-68004bdc5ab3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4"
      id="F_7a11fb32-345c-4e45-ba1b-74c6dad42763">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7LO#E%$H,'L#?+^6TKR?V!UL]0/$Y%]02P,$%     @ _(#'5I^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
M_(#'5I>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC '
MT"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2
M:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=
MI3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8
M%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+
M P04    " #\@,=6.JJBYT !   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U1
M76O#, S\*\8_8$G+5EAI!F/=1V%L91U]=V*E$;6M8*OMUE\_)2&LL)<]R3J)
MT]UY<:*X+XGVZLN[D K=,+?S+$M5 ]ZD*VHAR*2FZ U+&W=9:B,8FQH ]BZ;
MYODL\P:#OEN,7.N873;$4#%2$+ #M@BG]#OO6G7$A"4ZY.]"]V\'6GD,Z/$,
MMM"Y5JFATPM%/%-@XS95).<*/1D&6XB,U1]XTXG\-&7J$3;EAQ$AA9[E0EAC
M3-QO]/Q&-!Y!EH?NP/2$CB$N#<-SI$.+8=?1B(OLPD:?PUB'$.?Q/S%276,%
M2ZH.'@(/.49PG<"0&FR35L%X*/2XHNZ#58^!)22U"@.5['9.Y?3*#JY9Y%YD
M&.<H@[BR@_!1K84: ]@W.9 $E^2J=51=Z7FFUS>36TGHX-R#8._AE8P=S8\?
M=_<#4$L#!!0    ( /R QU8D'INBK0   /@!   :    >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*
MMR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>L
MXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5
M&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFN
MWPQP>'3^ 5!+ P04    " #\@,=699!YDAD!  #/ P  $P   %M#;VYT96YT
M7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;
M,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:
MMB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC
M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( /R QU8'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ _(#'5D=5.87N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ _(#'5IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #\
M@,=6R0'I)T\$  ",$   &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ _(#'5I^@&_"Q @  X@P   T
M         ( !D@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #\@,=6EXJ[
M',     3 @  "P              @ %N#P  7W)E;',O+G)E;'-02P$"% ,4
M    " #\@,=6.JJBYT !   \ @  #P              @ %7$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ _(#'5B0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ _(#'5F60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="staa-20230606.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="staa-20230606.htm">staa-20230606.htm</File>
    <File>staa-20230606.xsd</File>
    <File>staa-20230606_lab.xml</File>
    <File>staa-20230606_pre.xml</File>
    <File>staa-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "staa-20230606.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "staa-20230606.htm"
     ]
    },
    "labelLink": {
     "local": [
      "staa-20230606_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "staa-20230606_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "staa-20230606.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "staa",
   "nsuri": "http://www.staar.com/20230606",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-20230606.htm",
      "contextRef": "C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-20230606.htm",
      "contextRef": "C_d62f790e-4a8a-4ba3-ae89-0fb5b614b3e4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.staar.com/20230606/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-23-026811-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-026811-xbrl.zip
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M@I&3A,?Q")V(A"6!8#'JCH?<A3D&&CJ(8W0NW\K1.<]Y=L5#37;YW7ZO %@
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M*!(!S]8PCUM'6-<D$]2DSC:B3F#9Q/=^RT_#T>?O]EN]HA]__G]02P,$%
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MS2^N2^X>AL_D&=:D'Z;T%>ZH"IE0*PGDW>3I/?GRQ_B1/%+^;18H('<B7,7
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M;KBD+#*]YU+$MAS2C"8L*1T1$EVNYWR\UG6H!/,7/9&>TW+(2B$1D6C*>DO
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MV)2&[E$?BB<7?+<0=W?E;,UW"#%:YML-*>-Z2\2[/A Y>?YJ((3"OBF)>HE
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M] 967G@T%!HKD1\?;B4/3HM@9^Z]W]Q[1?J7*!M1VR">8]):Z-28]GRZ<!2
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M4JJ:3(G M;%9O7U&H$+\T4M!C3Y;..AF17J'FSLD7[NW7$JD:79U3K2""OQ
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MAW$2U6C+"5JHHRT2R:#6FSV(LX;M9I;44<B*6"JV62; I-J"^Z[8Q,,6 *-
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MY[H:ZFR0&6.U! OXS-"; ]B?OI--3D$TA;2%M[,2,<\>%T$3KK,HB;32I<]
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M0CVI@D9Q!5* YCRK1)"(%#\]F^0U?F3@)3.6LJ(F@Q([6UGT!2"Q8&MM=0]
MW$'_$K\-O36V&)T#@->+^1N%@6Y1(Z\1O%AP'E?_,$A9/>-/IVA5"MMQT_#8
M\V_(0- QT'Q];=>F/$BLDE>310M1;=%4)#TZ"<P^N8@Y5GK6B#*-\U$:CT]O
MAJ;<Q/!5F"V161O,ELA,>Q\F[?VL)7+=LR9ND4DN3=@ 3>4P7M0B5Q.\)E/$
M6.BLVRZ'+EC.(YST5YLG OVOHO99TLZ2]F0E[1_$LXHEO4>NU?7#BB>@*"@
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M6_'F9[]>^NKPNW_[[->;?EO_[G\ 4$L! A0#%     @ _(#'5O!2I\:(%
M*N(  !$              ( !     '-T86$M,C R,S V,#8N:'1M4$L! A0#
M%     @ _(#'5A@-E(H. P  H D  !$              ( !MQ0  '-T86$M
M,C R,S V,#8N>'-D4$L! A0#%     @ _(#'5HFMW)]?!@  ED(  !4
M         ( !]!<  '-T86$M,C R,S V,#9?;&%B+GAM;%!+ 0(4 Q0    (
M /R QU:)BI$0CP0  *HI   5              "  88>  !S=&%A+3(P,C,P
M-C V7W!R92YX;6Q02P$"% ,4    " #\@,=6MK)];TPP  ",.@$ #P
M        @ %((P  <W1A82UE>#DY7S$N:'1M4$L%!@     %  4 00$  ,%3
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
